Lack of cytomegalovirus transmission after pancreatic islet transplantation

Neal R. Barshes, Timothy C. Lee, F. Charles Brunicardi, Amy Mote, A. Paige Schock, Rodolfo Alejandro, Camillo Ricordi, John A. Goss

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In spite of antiviral prophylaxis, the transmission rate of cytomegalovirus (CMV) after solid organ transplantation remains high. In contrast, CMV transmission has never been reported following pancreatic islet transplantation (PIT). Eleven (seven CMV seronegative, four CMV seropositive) recipients underwent a total of 26 PITs. Following PIT recipients were monitored clinically and tested monthly for CMV antigenemia. Valganciclovir was given to all patients for 100 days after each PIT. Follow-up ranged from 6 to 24 months (median 14.5 months). Pancreatic islet grafts were procured from 18 CMV seropositive and 8 seronegative donors (69% and 31% of donors, respectively). In total there were 6 R+D+, 3 R+D-, 12 R-D+, and 5 R-D-PITs. No patient developed CMV antigenemia or symptoms consistent with CMV infection at any time following PIT. Routine posttransplant testing of PIT recipients demonstrated that neither CMV transmission nor CMV infection occurred after PIT.

Original languageEnglish
Pages (from-to)833-838
Number of pages6
JournalCell Transplantation
Volume13
Issue number7-8
StatePublished - Dec 1 2004

Fingerprint

Islets of Langerhans Transplantation
Cytomegalovirus
Transplantation (surgical)
Grafts
Cytomegalovirus Infections
Tissue Donors
Testing
Organ Transplantation
Islets of Langerhans
Antiviral Agents
Transplants

Keywords

  • β-Cell replacement
  • Antiviral prophylaxis
  • Cytomegalovirus (CMV)
  • Pancreatic islet transplantation (PIT)

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation

Cite this

Barshes, N. R., Lee, T. C., Brunicardi, F. C., Mote, A., Schock, A. P., Alejandro, R., ... Goss, J. A. (2004). Lack of cytomegalovirus transmission after pancreatic islet transplantation. Cell Transplantation, 13(7-8), 833-838.

Lack of cytomegalovirus transmission after pancreatic islet transplantation. / Barshes, Neal R.; Lee, Timothy C.; Brunicardi, F. Charles; Mote, Amy; Schock, A. Paige; Alejandro, Rodolfo; Ricordi, Camillo; Goss, John A.

In: Cell Transplantation, Vol. 13, No. 7-8, 01.12.2004, p. 833-838.

Research output: Contribution to journalArticle

Barshes, NR, Lee, TC, Brunicardi, FC, Mote, A, Schock, AP, Alejandro, R, Ricordi, C & Goss, JA 2004, 'Lack of cytomegalovirus transmission after pancreatic islet transplantation', Cell Transplantation, vol. 13, no. 7-8, pp. 833-838.
Barshes NR, Lee TC, Brunicardi FC, Mote A, Schock AP, Alejandro R et al. Lack of cytomegalovirus transmission after pancreatic islet transplantation. Cell Transplantation. 2004 Dec 1;13(7-8):833-838.
Barshes, Neal R. ; Lee, Timothy C. ; Brunicardi, F. Charles ; Mote, Amy ; Schock, A. Paige ; Alejandro, Rodolfo ; Ricordi, Camillo ; Goss, John A. / Lack of cytomegalovirus transmission after pancreatic islet transplantation. In: Cell Transplantation. 2004 ; Vol. 13, No. 7-8. pp. 833-838.
@article{245268e56f164e2cb5a5a8b43d95a861,
title = "Lack of cytomegalovirus transmission after pancreatic islet transplantation",
abstract = "In spite of antiviral prophylaxis, the transmission rate of cytomegalovirus (CMV) after solid organ transplantation remains high. In contrast, CMV transmission has never been reported following pancreatic islet transplantation (PIT). Eleven (seven CMV seronegative, four CMV seropositive) recipients underwent a total of 26 PITs. Following PIT recipients were monitored clinically and tested monthly for CMV antigenemia. Valganciclovir was given to all patients for 100 days after each PIT. Follow-up ranged from 6 to 24 months (median 14.5 months). Pancreatic islet grafts were procured from 18 CMV seropositive and 8 seronegative donors (69{\%} and 31{\%} of donors, respectively). In total there were 6 R+D+, 3 R+D-, 12 R-D+, and 5 R-D-PITs. No patient developed CMV antigenemia or symptoms consistent with CMV infection at any time following PIT. Routine posttransplant testing of PIT recipients demonstrated that neither CMV transmission nor CMV infection occurred after PIT.",
keywords = "β-Cell replacement, Antiviral prophylaxis, Cytomegalovirus (CMV), Pancreatic islet transplantation (PIT)",
author = "Barshes, {Neal R.} and Lee, {Timothy C.} and Brunicardi, {F. Charles} and Amy Mote and Schock, {A. Paige} and Rodolfo Alejandro and Camillo Ricordi and Goss, {John A.}",
year = "2004",
month = "12",
day = "1",
language = "English",
volume = "13",
pages = "833--838",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "7-8",

}

TY - JOUR

T1 - Lack of cytomegalovirus transmission after pancreatic islet transplantation

AU - Barshes, Neal R.

AU - Lee, Timothy C.

AU - Brunicardi, F. Charles

AU - Mote, Amy

AU - Schock, A. Paige

AU - Alejandro, Rodolfo

AU - Ricordi, Camillo

AU - Goss, John A.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - In spite of antiviral prophylaxis, the transmission rate of cytomegalovirus (CMV) after solid organ transplantation remains high. In contrast, CMV transmission has never been reported following pancreatic islet transplantation (PIT). Eleven (seven CMV seronegative, four CMV seropositive) recipients underwent a total of 26 PITs. Following PIT recipients were monitored clinically and tested monthly for CMV antigenemia. Valganciclovir was given to all patients for 100 days after each PIT. Follow-up ranged from 6 to 24 months (median 14.5 months). Pancreatic islet grafts were procured from 18 CMV seropositive and 8 seronegative donors (69% and 31% of donors, respectively). In total there were 6 R+D+, 3 R+D-, 12 R-D+, and 5 R-D-PITs. No patient developed CMV antigenemia or symptoms consistent with CMV infection at any time following PIT. Routine posttransplant testing of PIT recipients demonstrated that neither CMV transmission nor CMV infection occurred after PIT.

AB - In spite of antiviral prophylaxis, the transmission rate of cytomegalovirus (CMV) after solid organ transplantation remains high. In contrast, CMV transmission has never been reported following pancreatic islet transplantation (PIT). Eleven (seven CMV seronegative, four CMV seropositive) recipients underwent a total of 26 PITs. Following PIT recipients were monitored clinically and tested monthly for CMV antigenemia. Valganciclovir was given to all patients for 100 days after each PIT. Follow-up ranged from 6 to 24 months (median 14.5 months). Pancreatic islet grafts were procured from 18 CMV seropositive and 8 seronegative donors (69% and 31% of donors, respectively). In total there were 6 R+D+, 3 R+D-, 12 R-D+, and 5 R-D-PITs. No patient developed CMV antigenemia or symptoms consistent with CMV infection at any time following PIT. Routine posttransplant testing of PIT recipients demonstrated that neither CMV transmission nor CMV infection occurred after PIT.

KW - β-Cell replacement

KW - Antiviral prophylaxis

KW - Cytomegalovirus (CMV)

KW - Pancreatic islet transplantation (PIT)

UR - http://www.scopus.com/inward/record.url?scp=14044268808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14044268808&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 833

EP - 838

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 7-8

ER -